annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
Brd. 31B A phase I/II and pharmacologic study of MM-111 in patients with advanced,
refractory HER2-positive (HER2�) cancers. (Abstract #TPS169)
C. S. Denlinger, M. Beeram, A. W. Tolcher, L. J. Goldstein, W. J. Slichenmyer, J.
Murray, C. McDonagh, K. Andreas, V. M. Moyo
Brd. 31C SORAVE trial: Phase I sorafenib and everolimus in solid tumors. (Abstract
#TPS170)
L. Nogova, M. Scheffler, I. Papachristou, C. Mattonet, R. Krais, I. Katay, P.
Mallmann, U. Fuhr, M. Dietlein, J. Wolf
Brd. 32A A randomized, open-label phase IIb study of maintenence therapy with a
MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first
or second remission. (Abstract #TPS171)
H. J. Gray, A. A. Secord, M. L. Anderson, G. DelPriore, N. E. Tchabo, J. S. Berek
Brd. 32B Multiple tumor associated peptide vaccination as consolidation treatment in
women affected by breast and ovarian cancer. (Abstract #TPS172)
M. Nuti, F. Bellati, C. Napoletano, V. Visconti, M. Antonilli, H. Rahimi, S. Pauselli,
A. Rughetti, L. Frati, P. Benedetti Panici
Brd. 32C A phase II study of personalized selection of peptide vaccines combined with
conventional chemo- or endocrine therapy for refractory breast cancer.
(Abstract #TPS173)
U. Toh, H. Otsuka, N. Iwakuma, K. Shirouzu, E. Ogo, H. Yamana, K. Itoh, M.
Tanaka, T. Fujii
Brd. 33A A phase I study of NY-ESO-1 overlapping peptides with or without
incomplete Freund’s adjuvant and poly-ICLCL vaccination of ovarian cancer
patients in second or third clinical remission. (Abstract #TPS174)
C. S. Magid Diefenbach, P. Sabbatini, M. L. Hensley, J. A. Konner, W. P. Tew, G.
Ritter, A. Jungbluth, L. S. Pan, L. J. Old, S. Gnjatic
Brd. 33B Endogenous heat-shock protein vaccines for metastatic melanoma.
(Abstract #TPS175)
J. M. Heun, W. K. Nevala, M. R. Callstrom, T. D. Atwell, M. A. Farrell, E. Galanis, L.
Erickson, V. Suman, W. J. Charboneau, S. Markovic
Developmental Therapeutics—Experimental Therapeutics
Brd. 33C Investigation of pathways regulating early antiangiogenic response to
bevacizumab given prior to neoadjuvant breast cancer chemotherapy.
(Abstract #TPS176)
S. Mehta, S. P. Li, N. P. Hughes, R. F. Adams, A. R. Padhani, F. M. Buffa, C. A.
Wright, L. A. McRae, A. Makris, A. L. Harris
Brd. 34A A phase I study of cediranib plus whole-brain radiation therapy in patients
with brain metastases from non-small cell lung cancer. (Abstract #TPS177)
A. F. Eichler, H. A. Shih, L. V. Sequist, P. Y. Wen, R. K. Jain, A. G. Sorensen, T.
Batchelor
Brd. 34B Sorafenib (SOR) or placebo (PL) in combination with transarterial
chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma
(SPACE). (Abstract #TPS178^)
R. Lencioni, J. Zou, M. Leberre, G. Meinhardt, D. Voliotis, J. Bruix, J. M. Llovet
Brd. 34C Phase I study of ACE-041, a novel inhibitor of vascular maturation, in
patients with advanced solid tumors or relapsed/refractory multiple
myeloma. (Abstract #TPS179)
N. G. Borgstein, S. Sharma, J. C. Bendell, M. S. Gordon, H. Hurwitz, N. Solban, D.
Mitchell, S. Pearsall, C. H. Condon, M. L. Sherman
Brd. 35A A phase Ib study to evaluate the fully human monoclonal antibody
MNRP1685A (anti-NRP1) administered intravenously in combination with
bevacizumab with or without weekly paclitaxel in patients with advanced
solid tumors. (Abstract #TPS180)
A. Patnaik, C. D. Weekes, P. Hegde, Y. Xin, R. Yu, H. Xiang, R. K. Brachmann, P.
LoRusso
320